EVENT – Talk Bio

Vertex forges $2B-plus alliance with Enlaza to create new autoimmune drugs, improve conditioning methods

1 week ago talkbio0Tagged Autoimmune Diseases, conditioning regimens, covalent biologics, drug conjugates, engagers, Enlaza, gene therapy, T-Lymphocyte, War-Lock platform

Vertex Pharmaceuticals; Enlaza Therapeutics; autoimmune diseases; gene therapy; conditioning regimens; War-Lock platform; covalent biologics; drug conjugates; T-cell engagers; biotech alliance

Analysts Downplay Intellia Adverse Event, but Gene Therapy Safety Remains Under Scrutiny

3 months ago talkbio0Tagged Adverse event, ATTR-CM, Event, Gene Modification, gene therapy, Intellia, liver transaminase, MAGNITUDE trial, Response process, Safety, Stock Decline

Intellia Therapeutics; gene therapy; safety event; adverse event; MAGNITUDE trial; liver transaminase; stock decline; ATTR-CM; gene editing; analyst response

Lilly continues full-court press against breast cancer with women’s March Madness event sponsorships

5 months ago talkbio0Tagged Awareness, Basketball game, Eli Lilly, Event, Madness, Malignant neoplasm of breast, Woman

Eli Lilly, Woman, Madness, Malignant neoplasm of breast, Event, Awareness, Basketball game

Allakos Announces Discontinuation of AK006 Program and 75% Layoffs Following Clinical Trial Failures

8 months ago talkbio0Tagged AK006, Allakos, chronic, Clinical Trials, Dermatitis, Atopic, Failure (biologic function)

Allakos, AK006, clinical trial failure, layoffs, biotech, chronic spontaneous urticaria, atopic dermatitis

Allakos Discontinues AK006 Development, Cuts 75% of Workforce Amid Strategic Restructuring

8 months ago talkbio0Tagged AK006, Allakos, Biotechnology, Chronic Spontaneous Urticaria, Failure (biologic function), Financial cost, phase 1 trial, restructuring, strategic alternatives

Allakos, AK006, workforce reduction, strategic alternatives, Phase 1 trial failure, chronic spontaneous urticaria (CSU), biotechnology, restructuring costs.